“13 Years Running: DHG Pharma’s Stellar Performance in Vietnam’s Top 50 Listed Companies.”

As DHG Pharma approaches its 51st birthday, it continues to make its mark, earning a spot in the “Top 50 Best Listed Companies in Vietnam 2025” by Forbes Vietnam. Forbes evaluates businesses based on their financial performance, financial indicators, and ability to sustain long-term profits.

“Being recognized for 13 consecutive years is not just an affirmation of our leading position in the pharmaceutical industry, but also a meaningful gift to the entire DHG Pharma team, who are dedicated to continuing the resilient journey of serving the community’s health,” emphasized DHG Pharma’s General Director, Toshiyuki Ishii.

Solid Growth on a Strong Financial Foundation

Forbes’ quantitative assessments of DHG Pharma’s “financial health” acknowledge the company’s well-planned development strategy amid a volatile market. Meanwhile, the qualitative criteria reflect investors’ and consumers’ trust, further solidifying DHG Pharma’s reputation among domestic enterprises.

Specifically, DHG Pharma consistently delivers steady growth in revenue and profits. It stands out among listed companies with its mid-range capitalization and robust financial indicators, highly regarded by investors.

Of the three pharmaceutical companies in the Top 50 Forbes 2025, DHG Pharma maintains its leading position. The company ranks high for its long-established and trusted brand, dominating the market for over-the-counter drugs. Its distribution network has expanded to 30,000 traditional medicine stores (OTC), 3,546 outlets across 5 major pharmacy chains (MTC), and a presence in 3,200 hospitals and clinics (ETC) nationwide, along with exports to 20 countries.

DHG Pharma boasts a trusted and longstanding brand, dominating the market for over-the-counter drugs.

With two modern factories adhering to JAPAN GMP (Japan) and EU GMP (Europe) standards, DHG Pharma is now considered a benchmark for standardization, motivating the pharmaceutical industry to elevate its production processes and strive for “international-quality domestic drugs.” Only 10% of the industry’s factories meet similar high standards, with the remaining 90% adhering to WHO GMP standards, as of the end of 2024. The long-term involvement of strategic shareholder Taisho (Japan) has also contributed to standardized and transparent management and enhanced international collaboration.

The Top 50 Forbes 2025 ranking also measures brand value linked to social trust. DHG Pharma consistently earns consumers’ trust, as evidenced by accolades such as Top 10 Reputable Pharmaceutical Companies and Vietnamese High-Quality Products. Additionally, the company actively contributes to community well-being through over 100 health-focused programs annually.

Long-Term Development Strategy to Maintain Leading Position

The Top 50 Forbes 2025 list was announced as DHG Pharma is intensifying its long-term “growth axis” strategy, focusing on product restructuring and cost optimization across the pharmaceutical value chain.

According to General Director Toshiyuki Ishii, DHG Pharma has accelerated investments in technology and international production standards. Moving forward, the company will expand its production capacity, finalize EU-GMP standards for a new line, and embrace digital transformation and automation to enhance productivity and quality control.

Simultaneously, DHG Pharma is committed to new product development and technology transfer for renowned products from the Taisho Corporation (Japan) to strengthen its domestic competitiveness with a distinct product portfolio. In 2024, the company obtained registration numbers for 23 new products and commenced production for an additional 13 items.

Mr. Toshiyuki Ishii, General Director of DHG Pharma, shared that DHG Pharma will always uphold its mission of ‘For a healthier and more beautiful life,’ striving to be a symbol of reassurance and innovation in the pharmaceutical industry.

In addition to traditional distribution channels, the company is establishing e-commerce platforms. The international market is also being accelerated with a selective export strategy, focusing on potential markets and deeper penetration into ASEAN countries.

“Forbes’ recognition of DHG Pharma is not just about today’s business performance but also about our solid core values cultivated over half a century and our commitment to sustainable development in the future,” affirmed Mr. Toshiyuki Ishii. “We will always uphold our mission of ‘For a healthier and more beautiful life,’ striving to be a symbol of reassurance and innovation in the pharmaceutical industry.”